Skip to main content

Market Overview

Astellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies

  • Astellas Pharma Plc (OTCMKTS: ALPMY) has reported positive topline results from two Phase 3 trials, SKYLIGHT 1 and SKYLIGHT 2, evaluating an oral non-hormonal compound, fezolinetant, for treating moderate to severe vasomotor symptoms (VMS), specifically hot flashes associated with menopause.
  • Results showed that both trials met all four co-primary endpoints. It showed a statistically significant reduction from baseline in the frequency and severity of moderate to severe VMS to week four and week 12 for women receiving fezolinetant versus a placebo.
  • Furthermore, serious treatment-emergent adverse events occurred in less than 2% of patients, with headache being the most common adverse event.
  • The studies are progressing with patients completing a treatment duration of 52 weeks; results will be presented at a future medical meeting.
  • Fezolinetant is an NK3R inhibitor that blocks an essential peptide associated with downstream thermoregulation in the hypothalamus. 
  • Price Action: ALPMY shares gained 1.9% at $17.08 in market trading hours on the last check Friday.

Related Articles (ALPMY + ALPMF)

View Comments and Join the Discussion!

Posted-In: Phase 3 StudyBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at